SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

ProShares Trust - ProShares Ultra Bloomberg Natural Gas 2x Shares

ProShares Ultra Bloomberg Natural Gas

BOIL is trending due to surging natural gas futures prices, driven by forecasts of an extensive arctic cold snap and polar vortex across the US. This weather-driven demand is igniting a significant short squeeze, with the community actively discussing potential further upside and extreme volatility for leveraged natural gas products.

Netflix, Inc. engages in providing entertainment services. It also offers activities for leisure time, entertainment video, video gaming, and other sources of entertainment. It operates through the United States and International geographic segments. The company was founded by Marc Randolph and Wilmot Reed Hastings on August 29, 1997 and is headquartered in Los Gatos, CA.

Netflix Inc.

Netflix Inc

Netflix is trending following its recent earnings report, which, despite beating analyst expectations on key metrics, saw the stock experience a notable drop. Bulls view this as an oversold opportunity to buy, highlighting robust subscriber growth and expanding ad revenue, while bears point to cautious forward guidance and the pause in share buybacks as concerns, especially with the ongoing Warner Bros. acquisition discussions.

SPDR Gold Trust - SPDR Gold Shares

SPDR Gold Shares ETF

GLD is experiencing a powerful rally to record highs, driven by heightened geopolitical tensions, particularly concerns surrounding President Trump's tariff threats against European allies over Greenland. The community is actively discussing gold's role as a vital safe-haven, with many viewing it as a critical hedge against market instability and potential dollar weakness in a "risk-off" environment. This reflects a broad shift towards tangible assets amidst global uncertainty.

Intel Corp. engages in the design, manufacture, and sale of computer products and technologies. It delivers computer, networking, data storage, and communications platforms. The firm operates through the following segments: Client Computing Group (CCG), Data Center and AI (DCAI), Network and Edge (NEX), Mobileye, Accelerated Computing Systems and Graphics (AXG), Intel Foundry Services (IFS), and All Other. The CCG segment consists of platforms designed for notebooks, 2-in-1 systems, desktops, tablets, phones, wireless and wired connectivity products, and mobile communication components. The DCAI segment delivers solutions to cloud service providers and enterprise customers, along with silicon devices for communications service providers and high-performance computing customers. The NEX segment offers computing system solutions from inflexible fixed-function hardware to general-purpose compute, acceleration, and networking devices running cloud native software on programmable hardware. The Mobileye segment develops driving assistance and self-driving solutions. The AXG segment provides products and technologies designed to help customers solve the toughest computational problems. Its products include CPUs for high-performance computing and GPUs targeted for a range of workloads and platforms, from gaming and content creation on client devices to delivering media and gaming in the cloud, and the most demanding high-performance computing and AI workloads on supercomputers. The IFS segment refers to full stack solutions created from the foundry industry ecosystem. The All Other segment represents results from other non-reportable segments and corporate-related charges. The company was founded by Robert Norton Noyce and Gordon Earle Moore on July 18, 1968 and is headquartered in Santa Clara, CA.

Intel Corp.

Intel Corp

Intel is seeing a surge of positive sentiment, fueled by recent analyst upgrades citing robust demand for its server CPUs and advancements in its 18A manufacturing process, alongside widespread speculation of a significant US defense contract. The community is actively discussing Intel's competitive resurgence and potential to break key price resistance levels as its upcoming earnings report approaches, with many anticipating a strong turnaround in its domestic manufacturing capabilities.

America's Oil Reserve for the Digital Age

U.S Oil

US Oil Token (USOR) is currently trending due to highly volatile price action, sparking intense debate within the crypto community regarding its legitimacy. Many are warning of a potential "rug pull" or "pump and dump," while others are aggressively buying, anticipating significant gains tied to a speculated event by February 1st. Adding to the speculative fervor, prospective investors are actively seeking clarity on where to reliably purchase the Solana-based token amidst concerns about fake versions.

ProShares Trust - ProShares UltraShort Bloomberg Natural Gas -2x Shares

ProShares UltraShort Bloomberg Natural Gas

KOLD is trending amidst extreme volatility in natural gas prices, driven by rapidly shifting winter weather forecasts and a continuous tug-of-war between strong production and potential heating demand. The community is intensely focused on trading this inverse ETF, attempting to capitalize on sharp swings while navigating its 'widowmaker' reputation and inherent decay.

Ardelyx, Inc. is a biopharmaceutical company, which engages in the business of developing and commercializing biopharmaceutical products. The firm is also involved in developing a unique and innovative platform that enables the discovery of new biological mechanisms and pathways to develop potent and efficacious therapies that minimize the side effects and drug-drug interactions frequently encountered with traditional, systemically absorbed medicines. The company was founded by Dominique Charmot, Peter G. Schultz, and Jean M. Frechet in October 2007 and is headquartered in Waltham, MA.

Ardelyx Inc

Ardelyx is trending due to reports of Zydus Lifesciences considering a significant equity stake or acquisition, following a critical patent extension for its key products until 2041. The community is actively discussing a potential bidding war, believing the company's strong revenue trajectory and extended intellectual property runway make it considerably undervalued. Many see the patent extension as a "game changer," significantly enhancing the company's long-term appeal to major pharmaceutical players.

Corvus Pharmaceuticals, Inc. engages in the development of immune modulator product candidates with the potential to treat solid cancers, T-cell lymphomas, autoimmune diseases, and infectious diseases. Its product pipeline includes B Cell Activator and Anti-CD73, Adenosine Production Inhibitor Anti-CD73, ITK Inhibitor, A2AR Inhibitor, Anti-CXCR2, and A2BR Inhibitor. The company was founded by Richard A. Miller, Peter A. Thompson, Joseph J. Buggy, and Erik Verner on January 27, 2014 and is headquartered in South San Francisco, CA.

Corvus Pharmaceuticals Inc

Corvus Pharmaceuticals is currently trending due to compelling positive Phase 1 clinical trial data for its eczema drug, soquelitinib, demonstrating significant efficacy even in treatment-resistant patients. This promising data has sparked community discussions about the drug's blockbuster potential and the possibility of future partnerships within the large atopic dermatitis market. However, sentiment is divided as a recently announced public offering raises concerns about potential dilution, weighing on the stock's performance despite the favorable clinical results.

United States Commodity Funds LLC - United States Natural Gas Fund

United States Natural Gas Fund, LP

The United States Natural Gas Fund ($UNG) is experiencing significant upward momentum driven by widespread forecasts for brutal arctic cold and winter storms across key demand regions, sparking intense bullish sentiment. This sharp rebound is fueling active community debate, with many traders anticipating a short squeeze while others remain wary of natural gas's historical volatility and high production levels. Beyond immediate weather, the community is also discussing increasing long-term demand from LNG exports and emerging needs from AI data centers.

SSgA Active Trust - State Street Consumer Staples Select Sector SPDR ETF

Consumer Staples Select Sector SPDR Fund

The Consumer Staples Select Sector SPDR Fund (XLP) is trending as investors increasingly seek defensive assets, positioning it as a safe haven amidst broader market uncertainties. The community is actively discussing a significant sector rotation, with XLP experiencing a notable rally and challenging key technical resistance levels after a period of underperformance. Many view this shift as smart money moving into "risk-off" assets, highlighting the sector's potential for stability and continued upside.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Nordea Investment Management AB Grows Position in Arvinas, Inc. $ARVN

Nordea Investment Management AB raised its position in Arvinas, Inc. (NASDAQ:ARVN - Free Report) by 28.7% during the third quarter, according to its most recent filing with the Securities and...

Arvinas, Inc. $ARVN Stock Position Boosted by Campbell & CO Investment Adviser LLC

Campbell & CO Investment Adviser LLC lifted its stake in shares of Arvinas, Inc. (NASDAQ:ARVN - Free Report) by 307.7% during the third quarter, according to its most recent disclosure with the...

Arvinas, Inc. (NASDAQ:ARVN) Short Interest Down 27.9% in December

Arvinas, Inc. (NASDAQ:ARVN - Get Free Report) was the target of a significant decrease in short interest during the month of December. As of December 31st, there was short interest totaling 4,859,281...

Arvinas (NASDAQ:ARVN) Shares Gap Up - Time to Buy?

Arvinas (NASDAQ:ARVN) Shares Gap Up - Time to Buy...

Arvinas (NASDAQ:ARVN) Shares Down 2.6% - Should You Sell?

Arvinas (NASDAQ:ARVN) Trading Down 2.6% - Should You Sell...

Arvinas, Inc. (NASDAQ:ARVN) Given Consensus Recommendation of "Hold" by Brokerages

Shares of Arvinas, Inc. (NASDAQ:ARVN - Get Free Report) have been assigned a consensus rating of "Hold" from the twenty-three research firms that are presently covering the company, MarketBeat.com...

Caxton Associates LLP Takes $2.19 Million Position in Arvinas, Inc. $ARVN

Caxton Associates LLP bought a new stake in Arvinas, Inc. (NASDAQ:ARVN - Free Report) in the 2nd quarter, according to its most recent 13F filing with the SEC. The firm bought 298,062 shares of the...

Armistice Capital LLC Invests $4.12 Million in Arvinas, Inc. $ARVN

Armistice Capital LLC acquired a new stake in Arvinas, Inc. (NASDAQ:ARVN - Free Report) during the second quarter, according to its most recent Form 13F filing with the SEC. The firm acquired 560,000...

Arvinas, Inc. (NASDAQ:ARVN) Receives Average Recommendation of "Hold" from Analysts

Shares of Arvinas, Inc. (NASDAQ:ARVN - Get Free Report) have been assigned an average rating of "Hold" from the twenty-three research firms that are currently covering the stock, Marketbeat reports...

Velan Capital Investment Management LP Takes Position in Arvinas, Inc. $ARVN

Velan Capital Investment Management LP bought a new position in shares of Arvinas, Inc. (NASDAQ:ARVN - Free Report) during the second quarter, according to its most recent 13F filing with the...

Arvinas, Inc. is a biopharmaceutical company, which engages in the discovery, development, and commercialization of therapies to degrade disease-causing proteins. Its product candidates are ARV-110, a proteolysis targeting chimera (PROTAC) protein degrader that is in phase I clinical trial targeting the androgen receptor (AR) protein for the treatment of men with metastatic castration-resistant prostate cancer, ARV-471, and ARV-766, a PROTAC protein degrader targeting the estrogen receptor protein for the treatment of patients with metastatic ER positive/HER2 negative breast cancer. The company was founded in February 2013 and is headquartered in New Haven, CT.

Arvinas Inc

Up 10% or more

0% to up 9%

Down 1% to 9%

Down 10% or more

The S&P 500 enters 2026 after a strong run. What kind of return do you expect this year?

How will the S&amp;P 500 perform in 2026?

Fiscal Period	Estimated	Reported	Surprise	Result
Q4 '25	-$0.51	--	--	N/A
Q3 '25	-$0.71	-$0.48	32.10%	BEAT
Q2 '25	-$0.94	-$0.84	10.17%	BEAT
Q1 '25	-$0.96	$1.14	218.15%	BEAT
Q4 '24	-$0.96	-$0.63	34.06%	BEAT

ARVN
Arvinas Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Upcoming Earnings: Q4 '25

Historical Earnings

Latest ARVN News

ARVNArvinas Inc